
06/12/2025
The Mitochondrial Medicine Center at the Children's Hospital of Philadelphia is recruiting adults with MELAS to study an experimental new drug called “zagociguat”. It is currently not approved by the U.S. Food and Drug Administration or any other regulatory agencies for this disease; it is considered an investigational drug.
The study will last for approximately 8 months and will include at least 5 visits at CHOP and 4 additional visits that could either be scheduled in your home or at our hospital. Participants will be randomized to receive study drug for 12 weeks and placebo for 12 weeks, but you will not know which order. In addition to monitoring of your safety, the clinical trial also involves blood and urine tests, cardiac tests, physical exercise tests, and other study procedures. For more information: https://clinicaltrials.gov/study/NCT06402123
You will also receive travel support and reimbursement for related expenses.
We hope this research will contribute to the current knowledge of MELAS and improve treatment approaches. To learn more or inquire about this clinical trial, please contact our research coordinator, Sara Nguyen (nguyens2@chop.edu).